NOW APPROVED

Introducing CABLIVI:

The first and only FDA-approved therapy for aTTP

CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.